麗珠醫藥(01513.HK)年度純利增長20.39%至13.03億元 擬10派11.5元
格隆匯3月25日丨麗珠醫藥(01513.HK)發佈截至2019年12月31日止年度業績，2019年，集團實現營業收入人民幣93.847億元，同比增長5.91%；實現淨利潤人民幣14.6158億元，同比增長23.68%；實現歸屬於公司股東的淨利潤人民幣13.0288億元，同比增長20.39%；若剔除非經常性損益項目收益，公司2019年主營業務實現的歸屬於公司股東的淨利潤為人民幣11.9154億元，同比增長25.79%。董事會建議集團2019年度利潤分配預案為：以公司2019年末總股本為基數，每10股派發現金股利11.50元(含税)，本次不送紅股，不進行資本公積轉增股本。
2019年，集團進一步加強市場準入工作，提升對終端銷售人員的精細化考核及銷售市場的統籌管理，不斷擴大重點品種的醫院覆蓋率，艾普拉唑腸溶片增加反流性食管炎醫保報銷範圍，鹽酸呱羅匹隆片進入醫保常規目錄，注射用艾普拉唑鈉進入醫保談判目錄，都將有利於產品的市場推廣及未來銷售，對麗珠未來的經營業績產生積極影響；集團在全球範圍內積極開拓市場、發展及維護戰略合作，原料藥和中間體海外銷售佔比逐年提升，產品銷售已遍佈全球，製劑藥品國際市場推廣也不斷加大。研發方面，集團繼續以自主創新及高壁壘仿創為研發理念，以滿足未被滿足的臨牀需求為目標，不斷提升研發水平，優先推進重點在研品種的進展，探索原料－製劑一體化策略。
另外，集團生產與質量的管理水平穩步提升，在生產線達到國內GMP標準要求的同時，積極推進國際化認證。在戰略發展方面，集團通過在境內外設立公司及對外投資的方式，以提升麗珠股權投資的專業化水平、豐富麗珠現有的研發管線和發揮業務協同整合效應、及加快麗珠的國際化產業佈局。
展望2020年，麗珠將繼續肩負“麗珠世界、生命常青”的使命，以“一切歸零，重新創業”為發展理念，堅持高效務實、一絲不苟的工作態度，加大企業改革和創新力度，對標一流企業，齊心協力全面完成2020年任務。人才方面，要着重選人用人育人，採取內部培養和外部引進人才相結合的方式，錘鍊一支優秀高效的人才梯隊；生產方面，要把安全環保質量當作生命，同時嚴格控制成本；研發和銷售方面，要敢於創新及拼搏，不斷地推陳出新，不斷超越自我。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
